Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

ÀڱðæºÎ¾Ï º´±â ¥°B, ¥±A, ¥±B¿¡¼­ ¹æ»ç¼± ´Üµ¶Ä¡·á¼ºÀû ¥± ¹æ»ç¼± Ä¡·áÀÎÀÚ¿Í °ñ¹ÝÁ¾¾çÄ¡À¯¿ÍÀÇ °ü°è Irradiation alone in Stage IB, ¥±A, and ¥±B Cervix Cancer: ¥± Correlation between Treatment Factors and Pelvic Tumor Control

´ëÇѾÏÇÐȸÁö 1998³â 30±Ç 2È£ p.321 ~ 328
¼Ò¼Ó »ó¼¼Á¤º¸
¾È¼ºÀÚ/Sung Ja Ahn Á¤¿õ±â/³ªº´½Ä/³²ÅñÙ/ÃÖÈ£¼±/º¯Áö¼ö/Woong Ki Chung/Byung Sik Nah/Taek Keun Nam/Ho Sun Choi/Ji Soo Byun

Abstract

¸ñÀû : ±ÙÄ¡ ¸ñÀûÀÇ ¹æ»ç¼± ´Üµ¶Ä¡·á¸¦ ½ÃÇàÇÑ ÀڱðæºÎ¾Ï ȯÀÚÀÇ °ñ¹ÝÁ¾¾çÄ¡À¯¿¡ ¿µÇâÀ»
ÁÙ ¼ö ÀÖ´Â °ü·ÃÀÎÀÚ¸¦ ¾Ë¾Æº¸°íÀÚ ÈÄÇâÀû ºÐ¼®À» ½ÃÇàÇÏ¿´´Ù.
´ë»ó ¹× ¹æ¹ý : 1987³â 5¿ùºÎÅÍ 1991³â 12¿ù±îÁö ÀڱðæºÎ¾Ï º´±â IB, ¥±·Î Àü³²´ëÇб³º´
¿ø Ä¡·á¹æ»ç¼±°ú¿¡¼­ ±ÙÄ¡ ¸ñÀûÀÇ ¹æ»ç¼±Ä¡·á¸¦ ¿Ï·áÇÑ 220¸íÀÇ È¯ÀÚ¸¦ ´ë»óÀ¸·Î ºÐ¼®À» ½Ã
ÇàÇÏ¿´´Ù. ¸ðµç ȯÀÚ¿¡¼­ ¿ÜºÎ ¹æ»ç¼±Ä¡·á¿Í Àڱð­ ³» ±ÙÁ¢Ä¡·á¸¦ º´ÇàÇÏ¿´°í ±ÙÁ¢Ä¡·á´Â
°í¼±·®·ü Ä¡·á±âÀÇ ÇϳªÀÎ Buckler±âÁ¾À» »ç¿ëÇÏ¿´´Ù. Àüü ȯÀÚÀÇ ÃßÀû±â°£Àº 3¡­115°³¿ù
(Áß°£°ª: 62°³¿ù)À̾ú°í 97%ÀÇ È¯ÀÚ¿¡¼­ °ñ¹ÝÁ¾¾çÄ¡À¯ ÆÇÁ¤ÀÌ °¡´ÉÇÏ¿´´Ù.
°á°ú : ÀüüȯÀÚÀÇ Áß°£¿¬·ÉÀº 57¼¼¿´°í 97%ÀÇ È¯ÀÚ°¡ ÆíÆò»óÇǼ¼Æ÷¾ÏÀ̾úÀ¸¸ç º´±âº°
ºÐÆ÷´Â ¥°B1, ¥°B2, ¥±A,¥±B °¢°¢ 50, 15, 58, 97¸íÀ̾ú´Ù. A ±âÁØÁ¡ÀÇ ÃÑ ¹æ»ç¼± ¼±·®ÀÇ Áß
°£°ªÀº 7060 cGy¿´°í ÃÑ Ä¡·á±â°£ÀÇ ºÐÆ÷´Â 48¡­210ÀÏ·Î Áß°£°ªÀº 81ÀÏÀ̾ú´Ù º´±âº° 5³â
°ñ¹ÝÁ¾¾çÄ¡À¯À²Àº IB1, IB2, ¥±A, ¥±B¿¡¼­ °¢°¢ 98%, 87%, 75%, 64%ÀÇ °á°ú¸¦ º¸¿´´Ù. °ñ
¹ÝÁ¾¾çÄ¡À¯¿Í °ü·ÃµÈ ´Üµ¶º¯ÀÎ ºÐ¼® °á°ú, ȯÀÚÀÇ ³ªÀÌ°¡ 50¼¼ ÀÌ»óÀÏ ¶§, Á¶Á÷ÇÐÀûÀ¸·Î Æí
Æí»óÇǼ¼Æ÷¾ÏÀÎ °æ¿ì, Ãʱâ Hg¼öÄ¡°¡ 10g/dl ÀÌ»ó, ºÎºÐÀû °æºÎħÀ±¾Ï, °ñ¹Ý°­ ´ÜÃþÃÔ¿µ¼Ò°ß
¿¡¼­ ÀÓÆÄÀý ÀüÀÌ°¡ ¾ø¾ú´ø ±ºÀÌ ´ëÁ¶±º¿¡ ºñÇØ Åë°èÀûÀ¸·Î À¯ÀÇÇÑ ¼öÁØÀ¸·Î °ñ¹Ý Á¾¾çÄ¡À¯
À²ÀÌ ³ô¾Ò´Ù. ¹Ý¸é¿¡ ´Ùº¯ÀÎ ºÐ¼®¹ý¿¡¼­´Â º´±â, ÀÓÆÄÀý ÀüÀÌ À¯¹«, ÀڱðæºÎħÀ± Á¤µµ, Ä¡·á
±â°£, ³ªÀ̼øÀ¸·Î Åë°èÀûÀÎ À¯ÀǼºÀ» º¸¿´´Ù.
°á·Ð :º»¿ø¿¡¼­ »ç¿ëÇÏ°í ÀÖ´Â °í¼±·®·üÀÇ ±ÙÁ¢Ä¡·á¸¦ º´ÇàÇÑ ÀڱðæºÎ¾Ï º´±â IB, ¥±È¯
ÀÚÀÇ ¹æ»ç¼±Ä¡·á¿¡¼­ A ±âÁØÁ¡ÀÇ ¼±·® 7060 cGyÀº ÀûÀýÇÑ Ä¡·á¼±·®ÀÓÀ» ¾Ë ¼ö ÀÖ¾ú°í, ÇÊ
¿äÇÑ Ä¡·á±â°£ÀÇ Áö¿¬À» ¹æÁöÇÏ¸ç ±ÙÁ¢Ä¡·á¸¦ ¿ÜºÎ¹æ»ç¼± Ä¡·á ±â°£ Áß¿¡ ½Ç½ÃÇÏ¿© Ä¡·á±â
°£À» ÃÖ´ëÇÑÀ¸·Î ´ÜÃà½ÃÅ´À¸·Î °ñ¹ÝÁ¾¾çÄ¡À¯À²À» ³ôÀÏ ¼ö ÀÖÀ¸¸®¶ó »ç·áµÈ´Ù

INTRODUCTION
About 40% of the patients who have been diagnosed with invasive cervical cancer
who receive standard radical radiation therapy die from the disease, with many of these
patients suffer from uncontrolled local-regional tumor. The overall local control rate of
radiotherapy alone in stage I and ¥± cervix cancer patients was reported to be about75%
to 90% and the total pelvic failure rate in stage ¥°B, ¥±A, and ¥±B was 6.4%, 12.5%,
and 17.4%, respectively(1¡­6). Because radiation therapy is one of the locoregional
treatment modalities and the local control of the disease is first of all determinant to the
patient's survival and is the component we could increase the survival rate by the
improvement of the radiation therapy techniques we focused our attention to the
locoregional tumor effects of radiation through this analysis. The radiation effect on the
cervix cancer depends on the variable factors such as the host factors, tumor factors,
and treatment factors, which are usually interrelated in a complex mechanism. Also the
brachytherapy is very important component in the radiation therapy of cervix cancer
patients, but because the brachytherapy devices and radioactive source and its dose rate
is variable among the institutes, the direct comparison is controversial and difficult
problems. In our hospital we introduced the Buckler system at 1987, which is one of the
high dose rate model and has different radiobiological considerations comparing to the
historical conventional low dose rate brashy-therapy systems. For these reasons we
analyzed the data of the treated cervix cancer patients by radiotherapy alone from that
time to 1991 at the Department of Radiation Oncology, Chonnam University Hospital,
retrospectively and we assessed the effect of the possible parameters on the pelvic
tumor control in a group of radically irradiated patients with cervical cancer to find out
the clue solving the problems by defining the important parameters for the locoregional
control of the disease by the radiotherapy.

Å°¿öµå

ÀڱðæºÎ¾Ï; ±ÙÄ¡Àû ¹æ»ç¼±Ä¡·á; °ñ¹ÝÁ¾¾çÄ¡À¯;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

 

µîÀçÀú³Î Á¤º¸

KoreaMed
KAMS